Get the Stockscreener App
11.04
2.67%
+0.395
Cabaletta Bio Inc stock is currently priced at $11.04, with a 24-hour trading volume of 111.03K.
It has seen a +2.67% increased in the last 24 hours and a -35.02% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $10.52 pivot point. If it approaches the $11.17 resistance level, significant changes may occur.
Previous Close:
$10.64
Open:
$10.6
24h Volume:
111.03K
Market Cap:
$513.61M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-6.3815
EPS:
-1.73
Net Cash Flow:
$-54.24M
1W Performance:
-15.67%
1M Performance:
-35.02%
6M Performance:
-25.90%
1Y Performance:
-4.13%
1D Range:
$10.55
$11.03
52W Range:
$9.02
$26.35
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
267 759 3100
Address
2929 Arch Street, Suite 600, Philadelphia, PA
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Cramer: This REIT Is 'A Little Too Dicey'; As For Marathon Digital, 'Own The Pure'
Benzinga
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
GlobeNewswire Inc.
Verint Reports Strong Earnings, Joins Semtech, Alphabet And Other Big Stocks Moving Higher On Thursday
Benzinga
Analyst Ratings for Cabaletta Bio
Benzinga
Leslie's Posts Weak Earnings, Joins Las Vegas Sands, Verve Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga
Cabaletta Bio Inc Stock (CABA) Financials Data
Cabaletta Bio Inc (CABA) Net Income 2024
CABA net income (TTM) was -$67.67 million for the quarter ending December 31, 2023, a -27.75% decrease year-over-year.
Cabaletta Bio Inc (CABA) Cash Flow 2024
CABA recorded a free cash flow (TTM) of -$54.24 million for the quarter ending December 31, 2023, a -11.06% decrease year-over-year.
Cabaletta Bio Inc (CABA) Earnings per Share 2024
CABA earnings per share (TTM) was -$1.66 for the quarter ending December 31, 2023, a +8.29% growth year-over-year.
Cabaletta Bio Inc Stock (CABA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | See Remarks |
Jan 19 '24 |
Sale |
19.59 |
11,000 |
215,439 |
20,000 |
| Binder Gwendolyn | See Remarks |
Dec 19 '23 |
Option Exercise |
1.01 |
11,000 |
11,110 |
31,000 |
| Binder Gwendolyn | See Remarks |
Dec 19 '23 |
Sale |
21.89 |
11,000 |
240,789 |
20,000 |
| Binder Gwendolyn | See Remarks |
Nov 20 '23 |
Option Exercise |
1.01 |
11,000 |
11,110 |
31,000 |
| Binder Gwendolyn | See Remarks |
Nov 20 '23 |
Sale |
17.82 |
11,000 |
196,014 |
20,000 |
| Binder Gwendolyn | See Remarks |
Oct 19 '23 |
Option Exercise |
1.01 |
11,000 |
11,110 |
31,000 |
| Binder Gwendolyn | See Remarks |
Oct 19 '23 |
Sale |
13.36 |
11,000 |
146,921 |
20,000 |
| Binder Gwendolyn | See Remarks |
Sep 19 '23 |
Option Exercise |
1.01 |
11,000 |
11,110 |
31,000 |
| Binder Gwendolyn | See Remarks |
Sep 19 '23 |
Sale |
17.57 |
11,000 |
193,220 |
20,000 |
| Binder Gwendolyn | See Remarks |
Aug 21 '23 |
Option Exercise |
1.01 |
11,000 |
11,110 |
31,000 |
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
0.22%
0.88%
Cap:
|
Volume (24h):